Ritter Pharmaceuticals Inc (RTTR) Expected to Post Earnings of -$1.09 Per Share

Equities research analysts expect Ritter Pharmaceuticals Inc (NASDAQ:RTTR) to announce earnings of ($1.09) per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Ritter Pharmaceuticals’ earnings. Ritter Pharmaceuticals reported earnings per share of ($1.10) during the same quarter last year, which indicates a positive year-over-year growth rate of 0.9%. The firm is scheduled to issue its next quarterly earnings results on Monday, March 18th.

According to Zacks, analysts expect that Ritter Pharmaceuticals will report full year earnings of ($3.05) per share for the current year. For the next financial year, analysts anticipate that the business will report earnings of ($1.20) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that cover Ritter Pharmaceuticals.

Ritter Pharmaceuticals (NASDAQ:RTTR) last issued its quarterly earnings results on Friday, November 9th. The biotechnology company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.01.

Several brokerages have recently commented on RTTR. Zacks Investment Research cut shares of Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, January 16th. ValuEngine raised shares of Ritter Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Maxim Group reaffirmed a “hold” rating on shares of Ritter Pharmaceuticals in a research report on Thursday, December 20th. Finally, HC Wainwright set a $15.00 price target on shares of Ritter Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, October 15th.

A hedge fund recently raised its stake in Ritter Pharmaceuticals stock. Vanguard Group Inc boosted its holdings in Ritter Pharmaceuticals Inc (NASDAQ:RTTR) by 300.6% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 56,210 shares of the biotechnology company’s stock after acquiring an additional 42,180 shares during the period. Vanguard Group Inc owned about 0.98% of Ritter Pharmaceuticals worth $105,000 at the end of the most recent quarter. 12.55% of the stock is currently owned by institutional investors.

Shares of RTTR stock traded up $0.02 during trading hours on Tuesday, hitting $0.70. 641,400 shares of the company were exchanged, compared to its average volume of 221,514. Ritter Pharmaceuticals has a one year low of $0.47 and a one year high of $4.00. The stock has a market capitalization of $3.90 million, a price-to-earnings ratio of -0.14 and a beta of 1.45.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance.

Read More: Why do companies engage in swaps?

Get a free copy of the Zacks research report on Ritter Pharmaceuticals (RTTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit